TEVA - Alkermes Q3 Earnings Top Consensus On Track To Separate Oncology Business Reaffirms FY23 Outlook | Benzinga
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the consensus of $0.43.
The company reported revenues of $380.9 million, up from $252.4 million reported a year, beating the consensus estimate of $362.2 million.
Sales reflect the strong performance of the proprietary product portfolio (+16% Y/Y to $231.8 million).
As of Sept. 30, 2023, cash, cash equivalents and total investments stood at $995.6 million.
Richard Pops, CEO, said, "With solid performance across our proprietary commercial portfolio, the successful settlement of the VIVITROL® patent litigation, and progress toward completion of the ...